Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis

International Journal of Rheumatic Diseases

Volumn 20, Issue 11, 2017, Pages 1868-1871

  Umeda, Masataka ^a,b   Aramaki, Toshiyuki ^a   Fujikawa, Keita ^c   Iwamoto, Naoki ^b   Ichinose, Kunihiro ^b   Terada, Kaoru ^a   Takeo, Gou ^a   Yonemitsu, Nobuhisa ^a   Ueki, Yukitaka ^a   Migita, Kiyoshi ^d   Kawakami, Atsushi ^b  

^a SASEBO CHUO HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Department of Rheumatology Japan Community Healthcare Organization Isahaya General Hospital   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLCHICINE; PREDNISOLONE; TOCILIZUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CLINICAL ARTICLE; DELAYED DIAGNOSIS; DRUG EFFICACY; FAMILIAL MEDITERRANEAN FEVER; FASCIITIS; FEMALE; FEVER; GENE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; JAPANESE (PEOPLE); LEG PAIN; LEG SWELLING; LETTER; MEFV GENE; MIDDLE AGED; MUSCLE BIOPSY; MYALGIA; MYOSITIS; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; BIOPSY; COMPLICATION; IMMUNOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; FAMILIAL MEDITERRANEAN FEVER; FASCIITIS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYOSITIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84944535338     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12776     Document Type: Letter

References (13)

1. Samuels J, Aksentijevich I, Torosyan Y et al. (1998) Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 77, 268–97.
2. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 13, 344–7.
3. Livneh A, Langevitz P, Zemer D et al. (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40, 1879–85.
4. Migita K, Uehara R, Nakamura Y et al. (2012) Familial Mediterranean fever in Japan. Medicine (Baltimore) 91, 337–43.
5. Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30 (2), 138–43.
6. Langevitz P, Zemer D, Livneh A, Shemer J, Pras M (1994) Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol 21, 1708–9.
7. Gdynia HJ, Sperfeld AD, Haerter G (2006) Histologic signs of inflammatory myopathy in familial Mediterranean fever. J Clin Rheumatol 12, 265–6.
8. Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C, Sève P (2013) Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine 80, 645–9.
9. Mansfield E, Chae JJ, Komarow HD et al. (2001) The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 98, 851–9.
10. Bilgen SA, Kilic L, Akdogan A et al. (2011) Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 17, 358–62.
11. Fujikawa K, Migita K, Tsukada T et al. (2013) Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol 31 (3 Suppl. 77), 150–1.
12. Bagci S, Toy B, Tuzun A et al. (2004) Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 23, 333–7.
13. Hamanoue S, Suwabe T, Hoshino J et al. (2015) Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol 25, 1–4.